The Analyst (AZN) lowers the estimated FY2017 for Astrazeneca PLC

The Analyst (AZN) lowers the estimated FY2017 for Astrazeneca PLC

Astrazeneca PLC (NYSE:AZN) – Leerink Swann dropped their FY2017 earnings per share estimates for shares of Astrazeneca PLC in a research report issued to clients and investors on Thursday. Leerink Swann analyst S. Fernandez now forecasts that the firm will post earnings per share of $1.78 for the year, down from their previous estimate of $1.81. Leerink Swann currently has a “Hold” rating and a $34.00 target price on the stock. Leerink Swann also issued estimates for Astrazeneca PLC’s FY2019 earnings at $2.33 EPS and FY2020 earnings at $2.66 EPS.

Astrazeneca PLC (NYSE:AZN) last issued its earnings results on Thursday, July 28th. The company reported $0.83 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.76 by $0.07. The company had revenue of $5.60 billion for the quarter, compared to analysts’ expectations of $5.56 billion. Astrazeneca PLC had a net margin of 9.23% and a return on equity of 28.02%. Astrazeneca PLC’s quarterly revenue was down 4.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.21 EPS.

Other equities research analysts have also recently issued reports about the stock. Shore Capital restated a “hold” rating on shares of Astrazeneca PLC in a report on Wednesday, July 27th. Bank of America Corp. restated a “buy” rating and issued a $36.65 price target on shares of Astrazeneca PLC in a report on Monday, July 18th. Citigroup Inc. restated a “buy” rating on shares of Astrazeneca PLC in a report on Friday, September 23rd. Berenberg Bank restated a “buy” rating on shares of Astrazeneca PLC in a report on Sunday, September 11th. Finally, Beaufort Securities restated a “hold” rating on shares of Astrazeneca PLC in a report on Friday, August 26th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $37.44.

10/07/fy2017-eps-estimates-for-astrazeneca-plc-lowered-by-analyst-azn.html

Shares of Astrazeneca PLC (NYSE:AZN) traded down 0.077% during midday trading on Friday, hitting $32.235. 2,269,777 shares of the stock were exchanged. The stock has a market capitalization of $81.55 billion, a price-to-earnings ratio of 36.840 and a beta of 0.75. Astrazeneca PLC has a 1-year low of $26.97 and a 1-year high of $35.04. The firm’s 50 day moving average is $33.27 and its 200-day moving average is $30.76.

The firm also recently declared a dividend, which was paid on Monday, September 12th. Stockholders of record on Friday, August 12th were given a $0.44 dividend. The ex-dividend date of this dividend was Wednesday, August 10th. Astrazeneca PLC’s dividend payout ratio (DPR) is currently 78.29%.

Hedge funds have recently bought and sold shares of the stock. Forester Capital Management LTD raised its stake in Astrazeneca PLC by 68.4% in the first quarter. Forester Capital Management LTD now owns 3,200 shares of the company’s stock valued at $109,000 after buying an additional 1,300 shares during the period. First Interstate Bank raised its stake in Astrazeneca PLC by 233.3% in the second quarter. First Interstate Bank now owns 3,900 shares of the company’s stock valued at $118,000 after buying an additional 2,730 shares during the period. Synovus Financial Corp raised its stake in Astrazeneca PLC by 29.7% in the second quarter. Synovus Financial Corp now owns 4,372 shares of the company’s stock valued at $132,000 after buying an additional 1,000 shares during the period. Fifth Third Bancorp raised its stake in Astrazeneca PLC by 2.3% in the second quarter. Fifth Third Bancorp now owns 4,631 shares of the company’s stock valued at $140,000 after buying an additional 103 shares during the period. Finally, Integrated Investment Consultants LLC raised its stake in Astrazeneca PLC by 6.1% in the second quarter. Integrated Investment Consultants LLC now owns 4,756 shares of the company’s stock valued at $144,000 after buying an additional 275 shares during the period. 11.39% of the stock is currently owned by institutional investors.

Astrazeneca PLC Company Profile

Related posts

Leave a Comment